BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

California is not one of those states. Newsom in October rejected a $35 monthly insulin copay cap. In his veto message, he cited the state’s $100 million investment in insulin production as an example ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Discover the story of the Vickers 559, a British supersonic interceptor designed to outpace Soviet bombers. With advanced ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed 12:08 AM UTC Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound ...

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year.